Sinovac Biotech [SVA] vs Ingevity [NGVT] Detailed Stock Comparison
Sinovac Biotech
NASDAQ
Loading...
Ingevity
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Sinovac Biotech wins in 10 metrics, Ingevity wins in 7 metrics, with 0 ties. Sinovac Biotech appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Sinovac Biotech | Ingevity | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 6.66 | 12.96 | Sinovac Biotech |
| Price-to-Book Ratio | 0.05 | 16.67 | Sinovac Biotech |
| Debt-to-Equity Ratio | 0.02 | 1,139.77 | Sinovac Biotech |
| PEG Ratio | 0.02 | -0.27 | Ingevity |
| EV/EBITDA | -4.52 | 8.43 | Sinovac Biotech |
| Profit Margin (TTM) | 59.51% | -16.35% | Sinovac Biotech |
| Operating Margin (TTM) | -33.63% | 23.53% | Ingevity |
| EBITDA Margin (TTM) | N/A | 23.53% | N/A |
| Return on Equity | -0.88% | -106.83% | Sinovac Biotech |
| Return on Assets (TTM) | -0.78% | 8.90% | Ingevity |
| Free Cash Flow (TTM) | $-41.69M | $51.00M | Ingevity |
| Dividend Yield | 1,700.15% | N/A | N/A |
| 1-Year Return | 0.00% | 43.50% | Ingevity |
| Price-to-Sales Ratio (TTM) | 1.43 | 1.52 | Sinovac Biotech |
| Enterprise Value | $-328.71M | $3.31B | Ingevity |
| EV/Revenue Ratio | -0.73 | 2.50 | Sinovac Biotech |
| Gross Profit Margin (TTM) | 86.71% | 37.77% | Sinovac Biotech |
| Revenue per Share (TTM) | $5 | $36 | Ingevity |
| Earnings per Share (Diluted) | $-1.06 | $-5.95 | Sinovac Biotech |
| Beta (Stock Volatility) | N/A | 1.37 | N/A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Sinovac Biotech vs Ingevity Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Sinovac Biotech | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Ingevity | -0.83% | 2.41% | 19.45% | 30.16% | 14.30% | 39.50% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Sinovac Biotech | 0.00% | 0.00% | 0.00% | 15.95% | 71.16% | 75.34% |
| Ingevity | 43.50% | -23.43% | -4.88% | 108.15% | 108.15% | 108.15% |
Performance & Financial Health Analysis: Sinovac Biotech vs Ingevity
| Metric | SVA | NGVT |
|---|---|---|
| Market Information | ||
| Market Cap | $642.44M | $2.01B |
| Market Cap Category | Small cap | Mid cap |
| 10 Day Avg. Volume | N/A | 280,797 |
| 90 Day Avg. Volume | N/A | 270,826 |
| Last Close | $6.47 | $54.70 |
| 52 Week Range | $6.47 - $6.47 | $28.49 - $56.89 |
| % from 52W High | 0.00% | -3.85% |
| All-Time High | $12.50 (Aug 31, 2009) | $120.41 (Feb 18, 2019) |
| % from All-Time High | -48.24% | -54.57% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 1.84% | -0.07% |
| Quarterly Earnings Growth | 3.04% | -0.07% |
| Financial Health | ||
| Profit Margin (TTM) | 0.60% | -0.16% |
| Operating Margin (TTM) | -0.34% | 0.24% |
| Return on Equity (TTM) | -0.01% | -1.07% |
| Debt to Equity (MRQ) | 0.02 | 1,139.77 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $121.57 | $3.31 |
| Cash per Share (MRQ) | N/A | $2.11 |
| Operating Cash Flow (TTM) | $113.55M | $215.40M |
| Levered Free Cash Flow (TTM) | $-105,900,000 | $345.16M |
| Dividends | ||
| Last 12-Month Dividend Yield | 1,700.15% | N/A |
| Last 12-Month Dividend | $110.00 | N/A |
Valuation & Enterprise Metrics Analysis: Sinovac Biotech vs Ingevity
| Metric | SVA | NGVT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 6.66 | 12.96 |
| Forward P/E | -53.92 | 13.62 |
| PEG Ratio | 0.02 | -0.27 |
| Price to Sales (TTM) | 1.43 | 1.52 |
| Price to Book (MRQ) | 0.05 | 16.67 |
| Market Capitalization | ||
| Market Capitalization | $642.44M | $2.01B |
| Enterprise Value | $-328,711,264 | $3.31B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | -0.73 | 2.50 |
| Enterprise to EBITDA | -4.52 | 8.43 |
| Risk & Other Metrics | ||
| Beta | N/A | 1.37 |
| Book Value per Share (MRQ) | $121.57 | $3.31 |
Financial Statements Comparison: Sinovac Biotech vs Ingevity
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | SVA | NGVT |
|---|---|---|
| Revenue/Sales | $327.45M | $284.00M |
| Cost of Goods Sold | $43.53M | $170.60M |
| Gross Profit | $283.93M | $113.40M |
| Research & Development | $2.66M | $7.70M |
| Operating Income (EBIT) | $197.04M | $62.60M |
| EBITDA | $200.07M | $83.20M |
| Pre-Tax Income | $198.37M | $26.80M |
| Income Tax | $25.67M | $6.30M |
| Net Income (Profit) | $172.70M | $20.50M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | SVA | NGVT |
|---|---|---|
| Cash & Equivalents | $1.27B | $71.50M |
| Total Current Assets | $11.83B | $530.00M |
| Total Current Liabilities | $1.15B | $264.60M |
| Long-Term Debt | $217.09M | $1.37B |
| Total Shareholders Equity | $12.02B | $234.60M |
| Retained Earnings | $7.12B | $592.50M |
| Property, Plant & Equipment | $45.53M | $45.90M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | SVA | NGVT |
|---|---|---|
| Operating Cash Flow | $455.16M | $32.70M |
| Capital Expenditures | $-57.70M | N/A |
| Free Cash Flow | $423.23M | $15.40M |
| Debt Repayment | $-6.58M | $-100.30M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | SVA | NGVT |
|---|---|---|
| Shares Short | N/A | 1.12M |
| Short Ratio | N/A | 5.55 |
| Short % of Float | N/A | 0.04% |
| Average Daily Volume (10 Day) | N/A | 280,797 |
| Average Daily Volume (90 Day) | N/A | 270,826 |
| Shares Outstanding | 99.64M | 36.35M |
| Float Shares | N/A | 36.19M |
| % Held by Insiders | N/A | 0.01% |
| % Held by Institutions | N/A | 1.04% |
Dividend Analysis & Yield Comparison: Sinovac Biotech vs Ingevity
| Metric | SVA | NGVT |
|---|---|---|
| Last 12-Month Dividend | $110.00 | N/A |
| Last 12-Month Dividend Yield | 1,700.15% | N/A |
| 3-Year Avg Annual Dividend | $36.67 | N/A |
| 3-Year Avg Dividend Yield | 850.08% | N/A |
| 3-Year Total Dividends | $110.00 | N/A |
| Ex-Dividend Date | Jul 10, 2025 | N/A |